Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bifeprunox

Known as: 1-(2-Oxo-benzoxazolin-7-yl)-4-(3-biphenyl)methylpiperazinemesylate 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Serotonin 5-HT1A receptors are attractive targets for the development of improved antipsychotics. Indeed, extensive evidence in… Expand
2008
2008
Several novel antipsychotics activate serotonin 5-HT1A receptors as well as antagonising dopamine D2/3 receptors. Such a… Expand
2008
2008
Because long‐term antipsychotics elicit behavioral dopamine supersensitivity, the present study examined whether 7–9 days… Expand
Highly Cited
2008
Highly Cited
2008
RationaleBifeprunox is a partial dopamine agonist with a unique receptor-binding profile and potential antipsychotic properties… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2007
Highly Cited
2007
Aripiprazole is the first dopamine D(2) receptor partial agonist approved for use in schizophrenia and bipolar disorder. Other… Expand
2007
2007
Aripiprazole and the candidate antipsychotics, S33592, bifeprunox, N‐desmethylclozapine (NDMC) and preclamol, are partial… Expand
Highly Cited
2006
Highly Cited
2006
Dopamine D2 receptor antagonists induce hyperprolactinemia depending on the extent of D2 receptor blockade. We compared the… Expand
Highly Cited
2005
Highly Cited
2005
Several novel antipsychotics, such as aripiprazole, bifeprunox, SSR181507 [(3-exo)-8-benzoyl-N-(((2S)7-chloro-2,3-dihydro-1,4… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2005
Highly Cited
2005
Considerable interest has arisen in identifying antipsychotic agents with improved efficacy against negative symptoms, such as… Expand
Highly Cited
2005
Highly Cited
2005
Serotonin 5-HT1A receptors are promising targets in the management of schizophrenia but little information exists about affinity… Expand
  • table 2
  • table 3
  • figure 1
  • table 4
  • figure 2